Related Experiment Video
Updated: May 17, 2025

05:54
Preparation of a Non-Cardiomyocyte Cell Suspension for Single-Cell RNA Sequencing from a Post-Myocardial Infarction Adult Mouse Heart
Published on: February 3, 2023
1.9K
Single cell transcriptomic analyses of human heart failure with preserved ejection fraction
Biorxiv : the Preprint Server for Biology
|March 31, 2025
Summary
This study used single-nucleus RNA sequencing to analyze heart failure with preserved ejection fraction (HFpEF) and found distinct gene expression changes in cardiomyocytes. These findings offer new insights into HFpEF biology and potential therapeutic targets.
Area of Science:
- Cardiovascular Biology
- Genomics
- Translational Medicine
Background:
- Heart failure with preserved ejection fraction (HFpEF) is a complex, multi-system disease with significant morbidity and mortality.
- Understanding the underlying molecular mechanisms of HFpEF is crucial for developing effective treatments.
Purpose of the Study:
- To characterize cell-specific gene expression patterns in human HFpEF myocardium using single-nucleus RNA sequencing (snRNA-seq).
- To identify distinct transcriptional changes in various cell types within the HFpEF heart compared to non-failing controls.
Main Methods:
- Septal myocardial biopsies from HFpEF patients and controls were analyzed using snRNA-seq.
- Genotype-based demultiplexing (souporcell) was employed to assign nuclei to individual patients.
- Differential gene expression and functional pathway analyses were performed on identified cell types.
Main Results:
- Cardiomyocytes and fibroblasts exhibited the highest number of differentially expressed genes in HFpEF.
- Enriched pathways across multiple cell types included transcription/translation, immune activation, and metabolism.
- Transcriptional differences between HFpEF and dilated cardiomyopathy (DCM) were primarily observed in cardiomyocytes.
Conclusions:
- Genotype-based demultiplexing is effective for single-cell transcriptomic analysis of small biopsies.
- Cardiomyocytes show distinct transcriptional alterations in HFpEF, differentiating it from DCM.
- These findings highlight key HFpEF pathways and nominate potential therapeutic targets.

